8-K
filed November 22, 2022, 6:59 PM ET
ticker ACRS
CIK 0001557746
leadership
confidence high
sentiment neutral
materiality 0.65
Aclaris Therapeutics CEO Neal Walker to step down, becomes Chair; CFO Ruffo retires; Manion named CEO, Balthaser CFO
Aclaris Therapeutics, Inc.
- Neal Walker resigns as CEO effective Dec 31, 2022; appointed Chair of the Board effective Jan 1, 2023.
- CFO Frank Ruffo retires effective Dec 31, 2022; will serve as consultant through March 2, 2023.
- Douglas Manion, currently President, appointed CEO and Class I Director effective Jan 1, 2023.
- Kevin Balthaser, VP Finance since 2022, appointed CFO effective Jan 1, 2023.
- Christopher Molineaux becomes Lead Independent Director effective Jan 1, 2023.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Neal Walker was appointed as Chair of the Board at Aclaris Therapeutics, Inc..
- Action
- appointed
- Role
- Chair of the Board
Exact text from the filing
the Board appointed Dr. Walker as the Chair of the Board, effective January 1, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Frank Ruffo retired as Chief Financial Officer at Aclaris Therapeutics, Inc..
- Action
- retired
- Role
- Chief Financial Officer
Exact text from the filing
Mr. Ruffo notified the Company that he will retire from his positions as Chief Financial Officer and Corporate Secretary of the Company, effective December 31, 2022.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Douglas Manion was appointed as Chief Executive Officer at Aclaris Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
the Board appointed Douglas Manion, age 62, M.D., FRCP (C), as the Company’s Chief Executive Officer effective January 1, 2023, in addition to his role as President which he has held since August 2022.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Neal Walker resigned as Chief Executive Officer at Aclaris Therapeutics, Inc..
- Action
- resigned
- Role
- Chief Executive Officer
Exact text from the filing
Dr. Walker notified Aclaris Therapeutics, Inc. (the “ Company ”) that he will resign from his position as Chief Executive Officer of the Company, effective December 31, 2022.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kevin Balthaser was appointed as Chief Financial Officer at Aclaris Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
the Board appointed Kevin Balthaser as the Company’s Chief Financial Officer, effective as of January 1, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Douglas Manion was appointed as Class I Director at Aclaris Therapeutics, Inc..
- Action
- appointed
- Role
- Class I Director
Exact text from the filing
The Board also appointed Dr. Manion to the Board to serve as a Class I director to hold office until the 2025 annual meeting of stockholders
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Christopher Molineaux changed role as Lead Independent Director at Aclaris Therapeutics, Inc..
- Action
- assumed
- Role
- Lead Independent Director
Exact text from the filing
Christopher Molineaux will assume the role of Lead Independent Director on January 1, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.